Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...

Rybelsus reduced the risk of cardiovascular-related death, heart attack, and stroke by 14% compared to a placebo over an ...

Obesity and diabetes drugs, particularly semaglutides like Wegovy and Ozempic, may reduce a person’s risk of dementia, a new ...

Experts across healthcare debunk 15 common myths about GLP-1 medications—covering everything from access and cost to ...